Revolution Medicines (RVMD) Net Cash Flow (2019 - 2026)

Revolution Medicines' Net Cash Flow history runs 8 years deep, the most recent figure standing at $57.2 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 127.3% year-over-year to $57.2 million in Q1 2026; TTM through Mar 2026 was $108.5 million, a 137.05% increase from a year earlier, with the FY2025 full-year figure at -$158.2 million, down 3.77% from the prior year.
• Net Cash Flow fell to $57.2 million in Q1 2026 per RVMD's latest filing, from $166.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $342.6 million in Q4 2024 and bottomed at -$407.7 million in Q1 2024.
• The 5-year median for Net Cash Flow is -$10.8 million (2022), against an average of $19.7 million.
• Biggest YoY gain for Net Cash Flow was 2554.39% in 2023; the steepest drop was 667.35% in 2023.
• Year by year, Net Cash Flow stood at -$17.5 million in 2022, then jumped by 2030.45% to $338.4 million in 2023, then advanced by 1.25% to $342.6 million in 2024, then slumped by 51.46% to $166.3 million in 2025, then plunged by 65.61% to $57.2 million in 2026.
• Per Business Quant, the three latest RVMD Net Cash Flow figures stand at $57.2 million (Q1 2026), $166.3 million (Q4 2025), and -$184.1 million (Q3 2025).